Trial Search Results

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

AiCuris Anti-infective Cures GmbH

Collaborator: Quintiles, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: 60 mg AIC246
  • Drug: 120 mg AIC246
  • Drug: 240 mg AIC246
  • Other: Placebo

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Seropositive for HCMV IgG antibodies before transplantation

   - First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of
   the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's
   lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder

   - Evidence of post transplantation engraftment

   - Able to swallow tablets.

Exclusion Criteria:

   - Previous anti-HCMV therapy after this allogeneic HBPC transplantation

   - Mismatched or cord blood transplant recipients

   - Current or history of end-organ HCMV disease

   - Graft versus host disease (GVHD)

   - Impaired liver function

   - Reduced renal function

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
650-723-0822
Not Recruiting